Imexpharm

Imexpharm EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Imexpharm (IMP.VN) as of Oct 27, 2026 is 471.69 B VND. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 424.58 B VND — a change of 11.10% (higher).

EBITDA

471.69 BVND

YoY

11.10%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Imexpharm is 2025 471.69 B VND. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Imexpharm was 2024 424.58 B VND. It decreases by 11.10% higher compared to the previous year.

The Imexpharm EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
167.54 B VND
Jan 1, 2019
213.50 B VND
Jan 1, 2020
272.70 B VND
Jan 1, 2021
257.78 B VND
Jan 1, 2022
306.79 B VND
Jan 1, 2023
391.44 B VND
Jan 1, 2024
424.58 B VND
Jan 1, 2025
471.69 B VND
The Imexpharm EBITDA history
YEAREBITDAYoY
471.69 BVND+11.10%
424.58 BVND+8.47%
391.44 BVND+27.59%
306.79 BVND+19.01%
257.78 BVND-5.47%
272.70 BVND+27.73%
213.50 BVND+27.43%
167.54 BVND+19.91%
139.72 BVND+12.26%
124.46 BVND+11.67%
111.46 BVND+9.60%
101.69 BVND—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imexpharm Stock analysis

What does Imexpharm do? Imexpharm Corp manufactures and trades pharmaceuticals, medicinal chemicals, and botanical products, including antiseptics, traditional medicine, medical equipment, cosmetics, and supplemental food and drinks. The company provides packaging and warehousing services specifically for pharmaceutical storage. It also cultivates medicinal herbs. Imexpharm Corp serves the pharmaceutical industry and healthcare sector through its manufacturing, import, export, and trade operations, targeting businesses requiring medicinal products and services. The company's revenue streams include the sale of manufactured pharmaceuticals, imported and exported goods, and services such as packaging and warehousing. Its customers are businesses in the healthcare sector, including distributors and retailers of pharmaceuticals, medical equipment, and related products. The firm's operations span manufacturing, import, export, and trade, with additional services supporting the pharmaceutical supply chain. Imexpharm Corp's product portfolio covers a wide range of medicinal and health-related items, from antiseptics to supplemental food and drinks. The company's involvement in medicinal herb cultivation supports its production of traditional medicine and herbal-based products. This vertical integration enhances its ability to supply comprehensive solutions to healthcare businesses. Imexpharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imexpharm stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Imexpharm is 471.69 B VND in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Imexpharm changed from 424.58 B VND to 471.69 B VND, representing a 11.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Imexpharm since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s VND is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Imexpharm historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Imexpharm

All Key Metrics — Imexpharm